Future Directions in Graft Versus Host Disease
Closing the program on chronic graft versus host disease, the panelists share what they are most looking forward to in the space.
Discussion of Long-Term Effects of GVHD Therapy
Chronic GVHD specialists share commentary on long-term effects of graft versus host disease and therapies for the condition.
Therapy Selection for Patients with Chronic GVHD
The panel debates the various treatment options and comments on when they prefer each one.
Summary of Axatilimab for cGVHD
The clinical trial of a novel agent, axatilimab, is reviewed and analyzed.
Real-World Experience with Belumosudil
Clinical experiences with belusmosudil are shared among the panel.
The ROCKstar Study of Belumosudil in cGVHD
Corey Cutler explains the ROCKstar clinical trial of belumosudil for steroid-refractory chronic GVHD.
Clinical Experience with Ruxolitinib for cGVHD
Experienced hematologist-oncologists offer their clinical experiences with ruxolitinib.
The REACH3 Clinical Trial of Ruxolitinib in Chronic GVHD
Yi-Bin Chen reviews data from the REACH3 trial of ruxolitinib in patients with chronic steroid-refractory graft versus host disease.
The iNTEGRATE Trial: Ibrutinib With Prednisone as First-Line Therapy for cGVHD
The panel discusses the iNTERGRATE trial of ibrutinib in combination with prednisone as frontline therapy for chronic GVHD.
Ibrutinib as Second-Line Therapy for Steroid-Refractory Chronic GVHD
Catherine Lee reviews data on use of ibrutinib for steroid-refractory chronic graft versus host disease.
Therapy Options for Steroid-Refractory Chronic GVHD
Experts in the treatment of graft versus host disease evaluate second-line agents for patients with steroid-refractory disease.
Steroid-Refractory Chronic GVHD Background
The categories of steroid refractory gvhd are discussed: intolerant, unresponsive, and dependent.
Treatment Goals for a Patient With Chronic GVHD
The group discusses treatment goals and patient education for chronic GVHD.
Patient Case: A 48-Year-Old Man with Chronic GVHD
Dr Chen and Dr Cutler review a clinical case and discuss GVHD assessment for the patient.
The Chronic GVHD Treatment Paradigm
Dr Lee shares an overview of therapy and supportive care options for chronic GVHD according to the severity of a symptom.
The NIH Clinical Scoring of Organ Systems
Corey Cutler details the NIH Clinical Scoring of Organ System for chronic GHVD symptoms.
Assessment of Chronic GVHD Symptoms
Colleen Danielson, NP, walks through how chronic GVHD symptoms are assessed.
Identification of Patients at High Risk for GVHD
The panelists share their insights on the identification of patients at high risk for GVHD.
Statistics on the Incidence of Chronic GVHD
Dr Chen presents statistics on the incidence of chronic graft versus host disease.
Signs and Symptoms of Acute and Chronic GVHD
Colleen Danielson, NP shares the signs and symptoms she commonly sees in patients with graft versus host disease.
Current GVHD Prophylaxis Strategies
Yi-Bin Chen leads the panel in a review of various GVHD prophylaxis regimens.
Overview of GVHD Risk Factors
Catherine Lee explains risk factors that may contribute to the likelihood of a patient developing graft versus host disease.
Graft versus Host Disease Background
A panel of experts discusses the types of graft versus host disease and the biologic pathways that are thought to be involved.
Chronic GVHD: Prognoses and Future Directions in Care
Closing out their discussion on graft-versus-host disease, participants reflect on patient prognoses and the future directions of care.
Scenario 2: Treatment-Induced Damage in Chronic GVHD
A brief discussion on the risk of treatment-induced damage when managing patients with chronic graft-versus-host disease.
Scenario 2: Selecting Therapy for Steroid-Refractory GVHD
Having reviewed approved treatment options for steroid-refractory, chronic GVHD, experts discuss how they would address this patient scenario.
Scenario 2: Belumosudil and Axatilimab as Treatment Options in cGVHD
Considerations for belumosudil and axatilimab as treatment options for steroid-refractory chronic graft-versus-host disease.
Scenario 2: Ibrutinib and Ruxolitinib as Treatment Options in cGVHD
A review of treatment options approved for steroid-refractory chronic graft-versus-host disease starting with ibrutinib and ruxolitinib.
Scenario 2: Identifying Chronic GVHD and Risk Status
Shared insight on how to distinguish chronic GVHD from acute GVHD, as well as utilize appropriate methods to risk stratify disease.
Scenario 2: Challenges in Early Intervention for Chronic GVHD
Shifting their focus to chronic graft-versus-host disease, experts review a patient scenario and discuss the challenges in early intervention.
